Hanspeter GerberCSO & SVP at 3T Biosciences
Hans-Peter has over 25 years of R&D experience in oncology, including antibody-drug conjugates (ADCs), redirected T-cell targeting (bispecifics) and adoptive T-cell therapies. He built highly successful drug development teams in pharma, biotech and startup companies and oversaw the development and filings of over 10 INDs and contributed to 3 BLAs, including Avastin and two ADCs (Mylotarg, Besponsa). Hans-Peter is currently CSO at 3T Biosciences where he oversees target ID, platform- and preclinical program development of TCR-T cell and CD3-bispecific programs. He is an author on over 100 peer-reviewed papers in high impact journals in the field of oncology drug discovery.